Gilead Sciences, Inc.

GILD

$66.61

-4.8% (1 year change)

Avg closing price

Price range

Market Cap

$84.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$55.19 - $75.59

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

280.09x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$2.74 (4.07%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $84.3 Billion
Enterprise Value $109 Billion
Dividend Yield $2.74 (4.07%)
1 Year Return -0.8%
52-Week High $75.59
52-Week Low $55.19
Beta 0.44
Outstanding Shares 1.25 Billion
Avg 30 Day Volume 7.23 Million

Valuation

P/E Ratio 280.09
PEG 2440.52
Earnings per Share $0.24
Price to Sales Ratio 3.33
Price to Book Ratio 4.44
Revenue to Enterprise Value 4.26
EBIT to Enterprise Value 10.39
Total Debt to Enterprise Value 0.28
Debt to Equity 1.59

Profitability

Revenue $25.6 Billion
Gross Profit $20.6 Billion
EBIT $10.5 Billion
Net Income $301 Million
Profit Margin 1.18%
Quarterly Earnings Growth (YoY) +11.5%
Return on Equity 1.59%
Return on Assets 0.45%
Return on Invested Capital 18.13%

News

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Healthcare ...

Business Wire Business Wire, 4 months ago
What to make of Pfizer, Moderna insiders dumping stock? | Invezz

What to make of Pfizer, Moderna insiders dumping stock? | Invezz

Gilead Sciences says Veklury sales made up 25% of the total Q4 revenue. Gilead forecasts up to £18.34 billion of total product sales in fiscal 2021.

Invezz Invezz, 4 months ago
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach

Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new partnership with the Wake Forest University School of Divinity, one of the leading academic and fait...

Business Wire Business Wire, 4 months ago